Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer

VernacularTitle:免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用
Author: Yingxia SHI ¹ ; Lijun HU ; Jingping YU
Author Information

1. 大连医科大学研究生院，大连　116000
Keywords: Uterine cervical neoplasms; Immunotherapy; Immune checkpoint inhibitors
From: Journal of International Oncology 2022;49(9):568-571
CountryChina
Language:Chinese
Abstract: Most early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy. However, for patients with recurrent, metastatic cervical cancer, the available effective treatment is rare and the prognosis is poor. In recent years, with the development of immunotherapy, especially immune checkpoint inhibitors targeting programmed death-1 (PD-1) and its ligand (PD-L1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) , such as pembrolizumab, nivolumab, ipilimumab, has made breakthrough progress in the treatment of recurrent or metastatic cervical cancer.